Actively Recruiting
Clinical Trial of TQB3205 Capsule in Subjects With Advanced Malignant Tumors
Led by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Updated on 2026-04-20
156
Participants Needed
1
Research Sites
137 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The trial was divided into two phases: dose escalation and dose expansion. The dosing regimens were single-dose study and continuous dosing study. A single-center, open, non-randomized, single-arm clinical trial design was adopted. Subjects with advanced malignant tumors were selected to take TQB3205 capsules orally to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TQB3205 capsules.
CONDITIONS
Official Title
Clinical Trial of TQB3205 Capsule in Subjects With Advanced Malignant Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subjects voluntarily joined the study, signed informed consent form, and with good compliance.
- 18 years old or older.
- Eastern Cooperative Oncology Group (ECOG) physical status score of 0 or 1.
- Expected survival period of at least 3 months.
- At least one measurable lesion for efficacy evaluation.
- Normal function of main organs.
- Women of childbearing age agree to use effective contraception during the study and for 6 months after, with a negative pregnancy test within 7 days before enrollment.
- Men agree to use effective contraception during the study and for 6 months after.
You will not qualify if you...
- Major surgery, significant traumatic injury, or major surgery within 4 weeks prior to first medication (excluding specified surgeries), or long-term untreated wounds or fractures.
- Any bleeding or bleeding events grade 3 or higher within 4 weeks prior to first administration.
- Active syphilis infection needing treatment.
- History of psychotropic drug abuse or mental disorders unable to quit.
- Preparation for or history of allogeneic bone marrow or solid organ transplantation.
- History of hepatic encephalopathy.
- Active or uncontrolled infections grade 2 or higher.
- Renal failure requiring dialysis.
- History of immunodeficiency including HIV or other acquired/congenital immunodeficiency diseases.
- Epilepsy requiring treatment.
- Poorly controlled diabetes.
- Known allergy to study drugs or excipients.
- Participation in other anti-tumor clinical trials within 4 weeks before first medication.
- Any condition judged by the investigator to seriously endanger safety or affect study completion.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China, 300060
Actively Recruiting
Research Team
J
Jihui Hao, Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here